Vandana G Abramson
Overview
Explore the profile of Vandana G Abramson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hennessy M, Cimino-Mathews A, Carter J, Kachergus J, Ma Y, Leal J, et al.
Breast
. 2025 Mar;
81:104432.
PMID: 40049115
Background: Early metabolic change on PET/CT was predictive of response to neoadjuvant trastuzumab/pertuzumab (HP) in TBCRC026. We hypothesized that a composite biomarker incorporating PET/CT and HER2 tissue-based biomarkers could improve...
2.
Waks A, Chen E, Graham N, Frey A, Almeida K, Attaya V, et al.
JCO Oncol Pract
. 2024 Jul;
21(3):351-357.
PMID: 39028923
Purpose: The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce this time...
3.
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Breast Cancer Res Treat
. 2024 Jul;
207(2):275-282.
PMID: 38967884
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical...
4.
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Res Sq
. 2024 May;
PMID: 38746356
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical...
5.
Wescott E, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor B, Sanchez V, et al.
Cancer Res Commun
. 2024 Apr;
4(4):1120-1134.
PMID: 38687247
Significance: This translational study confirms the association of B7-H4 expression with a cold immune microenvironment in breast cancer and offers preclinical studies demonstrating a potential role for B7-H4 in suppressing...
6.
Lehmann B, Abramson V, Dees E, Shah P, Ballinger T, Isaacs C, et al.
JAMA Oncol
. 2023 Dec;
10(2):193-201.
PMID: 38095878
Importance: Agents targeting programmed death ligand 1 (PD-L1) have demonstrated efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are now the standard of care in patients with...
7.
Taylor B, Sun X, Gonzalez-Ericsson P, Sanchez V, Sanders M, Wescott E, et al.
Cancer Discov
. 2023 Oct;
14(2):290-307.
PMID: 37791898
Significance: Clinical resistance to immunotherapy is common in breast cancer, and many patients will likely require combination therapy to maximize immunotherapeutic benefit. This study demonstrates that heterogeneous MHC-I expression drives...
8.
Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, et al.
J Nucl Med
. 2023 Aug;
64(11):1690-1696.
PMID: 37652539
Predictive biomarkers of response to human epidermal growth factor receptor 2 (HER2)-directed therapy are essential to inform treatment decisions. The TBCRC026 trial reported that early declines in tumor SUVs corrected...
9.
Lenz L, Neff C, Solimeno C, Cogan E, Abramson V, Boughey J, et al.
Breast Cancer Res Treat
. 2023 Aug;
202(1):191-201.
PMID: 37589839
Purpose: A 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to identify HRD in patients with ovarian cancer using a threshold...
10.
Balbach M, Sherry A, Rexer B, Abramson V, Niermann K, Johnson C, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jul;
118(5):1262-1270.
PMID: 37433376
Purpose: Addition of adjuvant capecitabine improves overall survival for patients with breast cancer lacking pathologic complete response to standard-of-care neoadjuvant chemotherapy. Combining radiosensitizing capecitabine concurrent with radiation may further improve...